USNA USANA Health Sciences, Inc.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Investors need to pay close attention to USNA stock based on the movements in the options market lately.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

What a brutal six months it’s been for USANA. The stock has dropped 30.2% and now trades at $14.02, rattling many shareholders. This may have investors wondering how to approach the situation.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the personal care stocks, including USANA (NYSE:USNA) and its peers.

Consumer staples are considered safe havens in turbulent markets due to their inelastic demand profiles. On the other hand, they usually underperform during bull runs, and this paradigm has rung true over the past six months as the sector’s -4.8% decline paled in comparison to the S&P 500’s 10.5% gain.

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

USANA Health Sciences faced a challenging second quarter, with results missing Wall Street’s expectations and the market responding with a sharp decline. Management attributed underperformance to a non-cash goodwill impairment in its Hiya business and a packaging issue at Rise Wellness, both of which pressured operating margins. CEO Kevin Guest addressed these setbacks directly, acknowledging, “Hiya’s direct-to-consumer business has experienced a tougher and more expensive digital marketing envi

Venture brands stumble as digital marketing costs surge and goodwill impairment hits.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Usana's second-quarter report arrived with some worrying news for investors.

USANA Health Sciences (NYSE:USNA) said its core nutritional business remained in line with expectations during the second quarter of 2026, while near-term challenges at its Hiya and Rise Wellness ventures led the company to lower its full-year outlook. Chairman and Chief Executive Officer Kevin Gue

USANA Health Sciences (USNA) is back in focus after Q2 2026 results showed sales of $223.27 million, a swing to a net loss, lowered full year guidance, and a $29 million goodwill impairment charge. See our latest analysis for USANA Health Sciences. The Q2 2026 results and lowered guidance have coincided with sharp selling in USANA Health Sciences, with the share price down 34.2% over the past day and the 1-year total shareholder return down 48.29%, suggesting momentum has been weakening...

Despite a $29 million goodwill impairment and lowered full-year outlook, Usana's core business shows resilience with strong cash generation and promising growth in China and new product launches.

USANA Health (USNA) delivered earnings and revenue surprises of -116.28% and -4.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health and wellness products company USANA Health Sciences (NYSE:USNA) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 5.4% year on year to $223 million. On the other hand, the company’s full-year revenue guidance of $962.5 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP loss of $0.07 per share was significantly below analysts’ consensus estimates.

Health and wellness products company USANA Health Sciences (NYSE:USNA) will be reporting earnings this Tuesday after the bell. Here’s what to look for.

Shares of health and wellness products company USANA Health Sciences (NYSE:USNA) jumped 2.9% in the afternoon session after the company announced it renewed its partnership with Nordiq Canada, the national governing body for cross-country skiing, extending the agreement through the 2030 Olympic Winter Games. Under the renewed terms, USANA will continue its role as the official nutrition partner for Canada's elite cross-country ski athletes.The company will keep supplying its NSF Certified for Sp

Let’s dig into the relative performance of USANA (NYSE:USNA) and its peers as we unravel the now-completed Q1 personal care earnings season.